# DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma

> **NCT04834674** · PHASE2 · COMPLETED · sponsor: **Sichuan Cancer Hospital and Research Institute** · enrollment: 20 (actual)

## Conditions studied

- Intrahepatic Cholangiocarcinoma
- Transarterial Chemoembolization
- Apatinib
- PD-1 Antibody

## Interventions

- **COMBINATION_PRODUCT:** DEB-TACE combined with apatinib and PD-1 antibody

## Key facts

- **NCT ID:** NCT04834674
- **Lead sponsor:** Sichuan Cancer Hospital and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-01
- **Primary completion:** 2026-04-05
- **Final completion:** 2026-04-05
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04834674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04834674, "DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04834674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*